Physician profile
Janel Eckroth
NPI 1902167117
$1,733.00
in general payments reported to CMS, 2019-2025
19 companies · $536 in 2025
The $536 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.00 · 2022: $417 · 2023: $376 · 2024: $330 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207 · Education: $35.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.07 |
| Education | $35.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.88 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $202.16 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $178.89 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.15 | 2025 | |
| Edwards Lifesciences Corporation | $135.47 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| E.R. Squibb & Sons, L.L.C. | $107.53 | 2023-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $93.53 | 2022-2025 | Lifevest |
| Medtronic, INC. | $57.45 | 2024 | Corevalve Evolut R |
| Itamar Medical INC | $56.02 | 2023 | Watchpatone |
| Lexicon Pharmaceuticals, INC. | $42.33 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $41.02 | 2025 | Amvuttra |
| Pfizer INC. | $36.67 | 2025 | |
| Biotronik INC. | $33.42 | 2022 | |
| Abbott Laboratories | $31.01 | 2025 | Mini Trek |
| Chiesi USA, INC. | $29.51 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $25.11 | 2025 | Optimizer |
| Novo Nordisk INC | $23.25 | 2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $22.91 | 2025 | Verquvo |
| Lilly USA, LLC | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janel Eckroth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.